Artur Berkovitz
Research Subjects
Artur Berkovitz has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Kai Sonne
Clinic for Interventional Electrophysiology, Heart Centre Bad Neustadt , Von-Guttenberg-Straße 11, 97616 Bad Neustadt a. d. Saale , Germany
8 shared publications - Karin Nentwich
Heart Center Bad Neustadt, Clinic for Interventional Electrophysiology
8 shared publications - Thomas Deneke
Clinic for Interventional Electrophysiology, Heart Centre Bad Neustadt, 97616 Bad Neustadt a. d. Saale, Germany
8 shared publications - Elena Ene
Clinic for Interventional Electrophysiology, Heart Center RHÖN-KLINIKUM Campus Bad Neustadt , Bad Neustadt an der Saale
7 shared publications - Philipp Halbfass
Clinic for Invasive Electrophysiology Heart Center Bad Neustadt Bad Neustadt a.d. Saale Germany
6 shared publications - Julian Müller
Department of Cardiology, Universitäts-Herzzentrum Bad Krozingen, 79189 Bad Krozingen, Germany
3 shared publications
Latest Publications
- Open Access
- 7 March 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (4) , 1379-1391
Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation
Pulmonary vein isolation using radiofrequency ablation is an effective treatment option for patients with symptomatic atrial fibrillation (AF). Application of high power over a short period of time (HPSD) is reported to create more efficient lesions and may prevent collateral thermal oesophageal injury. This study aims to compare efficacy and safety of two different HPSD ablation approaches using different ablation index settings. Consecutive patients undergoing AF ablation with HPSD (50 W; ablation index–guided) using the ThermoCool SmartTouch SF catheter were included. Patients were grouped by ablation protocol: ablation with target ablation index (AI) of 400 on the anterior left atrial wall vs. 300 at the posterior left atrial wall (AI 400/300) or AI 450/350 was performed upon the operator’s preference and compared. Peri-procedural parameters and complications were recorded, and incidences of endoscopically detected thermal oesophageal lesions (EDEL) analysed. Recurrence rates after a mean follow-up of 25 ± 7 months and reconnection patterns in patients undergoing redo procedures were investigated. A total of 795 patients (67 ± 10 years; 58% male; 48% paroxysmal AF) underwent a first AF ablation with HPSD (211 in group AI 400/300 and 584 in group 450/350). Median procedure time was 82.9 ± 24.6 min with longer ablation times in patients with target AI 400/300 due to higher intraprocedural reconnection rates, increased box lesions, and additional right atrial isthmus ablations. EDEL rates among target AI 400/300 procedures were significantly lower (3% vs. 7%; P = 0.019). Correspondingly, AI 450/350 was the strongest independent predictor of post-ablation EDEL (OR 4.799, CI 1.427–16.138, P = 0.011). Twelve-month (76% vs. 76%; P = 0.892) and long-term ablation single procedure success (68% vs. 71%; log-rank P = 0.452) after a mean of 25 ± 7 months were comparable among both target AI groups; however, long-term success was significantly higher for paroxysmal AF compared to persistent AF (12 months: 80% vs. 72%; P = 0.010; end of follow-up: 76% vs. 65%; log-rank P = 0.001). One hundred three patients (16%) underwent a redo procedure during follow-up documented comparable pulmonary vein (PV) reconnection among groups. Multivariate predictors of AF recurrence were age, left atrium (LA) size, persistent AF, and extra-PV ablation targets. High-power short-duration AF ablation with target AI of 400 for non-posterior wall and 300 for posterior wall lesions resulted in comparable long-term results compared to higher AI (450/350) ablations with significantly lower risk for thermal oesophageal lesions. Older age, larger LA size, persistent AF, and extra-PV ablation targets were identified in a multivariate analysis as independent risk factors for recurrences of atrial arrhythmias.
- 7 March 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (4) , 1379-1391
Open AccessAcute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation
Pulmonary vein isolation using radiofrequency ablation is an effective treatment option for patients with symptomatic atrial fibrillation (AF). Application of high power over a short period of time (HPSD) is reported to create more efficient lesions and may prevent collateral thermal oesophageal injury. This study aims to compare efficacy and safety of two different HPSD ablation approaches using different ablation index settings. Consecutive patients undergoing AF ablation with HPSD (50 W; ablation index–guided) using the ThermoCool SmartTouch SF catheter were included. Patients were grouped by ablation protocol: ablation with target ablation index (AI) of 400 on the anterior left atrial wall vs. 300 at the posterior left atrial wall (AI 400/300) or AI 450/350 was performed upon the operator’s preference and compared. Peri-procedural parameters and complications were recorded, and incidences of endoscopically detected thermal oesophageal lesions (EDEL) analysed. Recurrence rates after a mean follow-up of 25 ± 7 months and reconnection patterns in patients undergoing redo procedures were investigated. A total of 795 patients (67 ± 10 years; 58% male; 48% paroxysmal AF) underwent a first AF ablation with HPSD (211 in group AI 400/300 and 584 in group 450/350). Median procedure time was 82.9 ± 24.6 min with longer ablation times in patients with target AI 400/300 due to higher intraprocedural reconnection rates, increased box lesions, and additional right atrial isthmus ablations. EDEL rates among target AI 400/300 procedures were significantly lower (3% vs. 7%; P = 0.019). Correspondingly, AI 450/350 was the strongest independent predictor of post-ablation EDEL (OR 4.799, CI 1.427–16.138, P = 0.011). Twelve-month (76% vs. 76%; P = 0.892) and long-term ablation single procedure success (68% vs. 71%; log-rank P = 0.452) after a mean of 25 ± 7 months were comparable among both target AI groups; however, long-term success was significantly higher for paroxysmal AF compared to persistent AF (12 months: 80% vs. 72%; P = 0.010; end of follow-up: 76% vs. 65%; log-rank P = 0.001). One hundred three patients (16%) underwent a redo procedure during follow-up documented comparable pulmonary vein (PV) reconnection among groups. Multivariate predictors of AF recurrence were age, left atrium (LA) size, persistent AF, and extra-PV ablation targets. High-power short-duration AF ablation with target AI of 400 for non-posterior wall and 300 for posterior wall lesions resulted in comparable long-term results compared to higher AI (450/350) ablations with significantly lower risk for thermal oesophageal lesions. Older age, larger LA size, persistent AF, and extra-PV ablation targets were identified in a multivariate analysis as independent risk factors for recurrences of atrial arrhythmias.
- 8 August 2022
- Published by Georg Thieme Verlag KG in Aktuelle Kardiologie
- Vol. 11 (04) , 321-326
Herzinsuffizienz und Vorhofflimmern – eine Zwillingsepidemie
Vorhofflimmern (VHF) und eine Herzinsuffizienz begünstigen sich gegenseitig und treten häufig in Kombination auf. Eine effektive Therapie des VHF inklusive der möglicherweise notwendigen Antikoagulation sollte zentraler Baustein bei Patienten mit eingeschränkter systolischer Funktion und VHF sein. Medikamentöse Therapieoptionen sind in der Regel wenig effektiv, sodass zunehmend Katheterablationsverfahren zur Behandlung dieser Patienten in den Vordergrund gestellt werden. Randomisierte Studien bei selektierten Patienten zeigen nicht nur einen symptomatischen Effekt auf die Herzinsuffizienz, sondern neben Verbesserung der LV-Funktion auch einen Letalitätsbenefit der effektiven Ablation von VHF. In der Zukunft gilt es, Patienten sinnvoll für die Katheterablation zu identifizieren. Ob das reine Vorhandensein von VHF oder eher die VHF-Last bei Patienten mit Herzinsuffizienz entscheidend für die Prognose ist, wird aktuell in weiteren Studien untersucht. Atrial fibrillation (AF) and heart failure are mutually beneficial and often occur in combination. Effective therapy of AF, including potentially necessary anticoagulation, should be a central component in patients with impaired systolic function and AF. Drug therapy options are generally ineffective, so catheter ablation procedures are increasingly being emphasized to treat these patients. Randomized trials in selected patients show not only a symptomatic effect on heart failure but also a mortality benefit of effective ablation of AF in addition to improvement in LV function. In the future, it will be important to identify patients for catheter ablation in a meaningful way. Whether the presence of AF or rather the AF burden is crucial for prognosis in patients with heart failure is currently being investigated in further studies. Article published online: 08 August 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 8 August 2022
- Published by Georg Thieme Verlag KG in Aktuelle Kardiologie
- Vol. 11 (04) , 321-326
Herzinsuffizienz und Vorhofflimmern – eine Zwillingsepidemie
Vorhofflimmern (VHF) und eine Herzinsuffizienz begünstigen sich gegenseitig und treten häufig in Kombination auf. Eine effektive Therapie des VHF inklusive der möglicherweise notwendigen Antikoagulation sollte zentraler Baustein bei Patienten mit eingeschränkter systolischer Funktion und VHF sein. Medikamentöse Therapieoptionen sind in der Regel wenig effektiv, sodass zunehmend Katheterablationsverfahren zur Behandlung dieser Patienten in den Vordergrund gestellt werden. Randomisierte Studien bei selektierten Patienten zeigen nicht nur einen symptomatischen Effekt auf die Herzinsuffizienz, sondern neben Verbesserung der LV-Funktion auch einen Letalitätsbenefit der effektiven Ablation von VHF. In der Zukunft gilt es, Patienten sinnvoll für die Katheterablation zu identifizieren. Ob das reine Vorhandensein von VHF oder eher die VHF-Last bei Patienten mit Herzinsuffizienz entscheidend für die Prognose ist, wird aktuell in weiteren Studien untersucht. Atrial fibrillation (AF) and heart failure are mutually beneficial and often occur in combination. Effective therapy of AF, including potentially necessary anticoagulation, should be a central component in patients with impaired systolic function and AF. Drug therapy options are generally ineffective, so catheter ablation procedures are increasingly being emphasized to treat these patients. Randomized trials in selected patients show not only a symptomatic effect on heart failure but also a mortality benefit of effective ablation of AF in addition to improvement in LV function. In the future, it will be important to identify patients for catheter ablation in a meaningful way. Whether the presence of AF or rather the AF burden is crucial for prognosis in patients with heart failure is currently being investigated in further studies. Article published online: 08 August 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 2 February 2022
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (6) , 928-937
Acute oesophageal safety of high-power short duration with 50 W for atrial fibrillation ablation
Pulmonary vein isolation (PVI) using radiofrequency (RF) ablation is an effective treatment option for patients with atrial fibrillation (AF). This study aims to investigate the safety of high-power short duration (HPSD) with emphasis on oesophageal lesions after PVI. Consecutive patients undergoing AF ablation with HPSD (50 W; ablation index (AI)-guided; target AI 350 for posterior wall ablation, AI 450 for anterior wall ablation) using the ThermoCool SmartTouch SF catheter were included. Patients underwent post-ablation oesophageal endoscopy to detect and categorize thermal oesophageal injury (EDEL). Occurrence and risk factors of oesophageal lesions and perforating complications were analysed. A total of 1033 patients underwent AF ablation with HPSD. Of them, 953 patients (67.6 ± 9.6 years; 58% male; 43% paroxysmal AF; 68% first PVI) underwent post-procedural oesophageal endoscopy and were included in further analyses. Median procedure time was 82.8 ± 24.4 min with ablation times of 16.1 ± 9.2 min. Thermal oesophageal injury was detected in 58 patients (6%) (n = 29 Category 1 erosion, n = 29 Category 2 ulcerous). One patient developed oesophageal perforation (redo, 4th AF ablation). No patient died. Using multivariable regression models, increased total ablation time [odds ratio (OR) 1.029, P = 0.010] and history of stroke (OR 2.619, P = 0.033) were associated with increased incidence of EDEL after AF ablation, whereas increased body mass index was protective (OR 0.980, P = 0.022). Thermal oesophageal lesions occur in 6% of HPSD AF ablations. The risk for development of perforating complications seems to be low. Incidence of atrio-oesophageal fistula (0.1%) is comparable to other reported series about RF ablation approaches.
- 2 February 2022
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (6) , 928-937
Acute oesophageal safety of high-power short duration with 50 W for atrial fibrillation ablation
Pulmonary vein isolation (PVI) using radiofrequency (RF) ablation is an effective treatment option for patients with atrial fibrillation (AF). This study aims to investigate the safety of high-power short duration (HPSD) with emphasis on oesophageal lesions after PVI. Consecutive patients undergoing AF ablation with HPSD (50 W; ablation index (AI)-guided; target AI 350 for posterior wall ablation, AI 450 for anterior wall ablation) using the ThermoCool SmartTouch SF catheter were included. Patients underwent post-ablation oesophageal endoscopy to detect and categorize thermal oesophageal injury (EDEL). Occurrence and risk factors of oesophageal lesions and perforating complications were analysed. A total of 1033 patients underwent AF ablation with HPSD. Of them, 953 patients (67.6 ± 9.6 years; 58% male; 43% paroxysmal AF; 68% first PVI) underwent post-procedural oesophageal endoscopy and were included in further analyses. Median procedure time was 82.8 ± 24.4 min with ablation times of 16.1 ± 9.2 min. Thermal oesophageal injury was detected in 58 patients (6%) (n = 29 Category 1 erosion, n = 29 Category 2 ulcerous). One patient developed oesophageal perforation (redo, 4th AF ablation). No patient died. Using multivariable regression models, increased total ablation time [odds ratio (OR) 1.029, P = 0.010] and history of stroke (OR 2.619, P = 0.033) were associated with increased incidence of EDEL after AF ablation, whereas increased body mass index was protective (OR 0.980, P = 0.022). Thermal oesophageal lesions occur in 6% of HPSD AF ablations. The risk for development of perforating complications seems to be low. Incidence of atrio-oesophageal fistula (0.1%) is comparable to other reported series about RF ablation approaches.
- 10 November 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (3) , 400-405
Safety of very high-power short-duration radiofrequency ablation for pulmonary vein isolation: a two-centre report with emphasis on silent oesophageal injury
Aims: Very high-power short-duration (vHPSD) via temperature-controlled ablation (TCA) is a new modality to perform radiofrequency pulmonary vein isolation (PVI), conceivably at the cost of a narrower safety margin towards the oesophagus. In this two-centre trial, we aimed to determine the safety of vHPSD-based PVI with specific emphasis on silent oesophageal injury. Methods and results: Ninety consecutive patients with atrial fibrillation (AF) underwent vHPSD-PVI (90 W, 3–4 s, TCA) using the QDOT MICRO catheter, in conjunction with the nGEN (Bad Neustadt, n = 45) or nMARQ generator (Bruges, n = 45). All patients underwent post-ablation oesophageal endoscopy. Procedural parameters and complications were recorded. A subgroup of 21 patients from Bad Neustadt underwent cerebral magnetic resonance imaging (cMRI) to detect silent cerebral events (SCEs). Mean age was 67 ± 9 years, 59% patients were male, and 66% patients had paroxysmal AF. Pulmonary vein isolation was obtained in all cases after 96 ± 29 min. No steam pop, cardiac tamponade, stroke, or fistula was reported. None of the 90 patients demonstrated oesophageal ulceration (0%). Charring was not observed in the nMARQ cohort (0% vs. 11% in the nGEN group). In 5 out of 21 patients (24%), cMRI demonstrated SCE (exclusively nGEN cohort). Conclusion: Temperature-controlled vHPSD catheter ablation allows straightforward PVI without evidence of oesophageal ulcerations or symptomatic complications. Catheter tip charring and silent cerebral lesions when using the nGEN generator have led to further modification.
- 10 November 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (3) , 400-405
Safety of very high-power short-duration radiofrequency ablation for pulmonary vein isolation: a two-centre report with emphasis on silent oesophageal injury
Aims: Very high-power short-duration (vHPSD) via temperature-controlled ablation (TCA) is a new modality to perform radiofrequency pulmonary vein isolation (PVI), conceivably at the cost of a narrower safety margin towards the oesophagus. In this two-centre trial, we aimed to determine the safety of vHPSD-based PVI with specific emphasis on silent oesophageal injury. Methods and results: Ninety consecutive patients with atrial fibrillation (AF) underwent vHPSD-PVI (90 W, 3–4 s, TCA) using the QDOT MICRO catheter, in conjunction with the nGEN (Bad Neustadt, n = 45) or nMARQ generator (Bruges, n = 45). All patients underwent post-ablation oesophageal endoscopy. Procedural parameters and complications were recorded. A subgroup of 21 patients from Bad Neustadt underwent cerebral magnetic resonance imaging (cMRI) to detect silent cerebral events (SCEs). Mean age was 67 ± 9 years, 59% patients were male, and 66% patients had paroxysmal AF. Pulmonary vein isolation was obtained in all cases after 96 ± 29 min. No steam pop, cardiac tamponade, stroke, or fistula was reported. None of the 90 patients demonstrated oesophageal ulceration (0%). Charring was not observed in the nMARQ cohort (0% vs. 11% in the nGEN group). In 5 out of 21 patients (24%), cMRI demonstrated SCE (exclusively nGEN cohort). Conclusion: Temperature-controlled vHPSD catheter ablation allows straightforward PVI without evidence of oesophageal ulcerations or symptomatic complications. Catheter tip charring and silent cerebral lesions when using the nGEN generator have led to further modification.
- Open Access
- 21 July 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (8) , 1136-1138
Esophagopericardial Fistula
- 21 July 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (8) , 1136-1138
Open AccessEsophagopericardial Fistula
- Open Access
- 13 January 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (3) , 695-703
Incidence of ablation‐induced esophageal injury associated with high‐power short duration temperature‐controlled pulmonary vein isolation using a specialized open‐irrigated ablation catheter: A retrospective single‐center study
Introduction: To evaluate short‐term efficacy and incidence of ablation‐induced endoscopically detected esophageal injury in patients undergoing high‐power, short‐duration (HPSD) pulmonary vein isolation using a novel irrigated radiofrequency ablation catheter and ablation generator setup.Methods and Results: Atrial fibrillation (AF) patients, who underwent AF ablation using an irrigated radiofrequency ablation catheter specifically designed for a HPSD ablation approach (50 W, with a target Ablation Index of 350 at posterior wall), received postablation esophageal endoscopy after ablation. In total 45 consecutive patients (67 ± 10 years; 58% male; 42% paroxysmal AF) undergoing AF ablation using a specialized ablation catheter (QDOT) were included in the study. Thirty‐one of 45 patients (69%) underwent a first‐time pulmonary vein isolation (Group 1, 67 ± 11 years; 55% male; 48% paroxysmal AF). Fourteen patients (31%) underwent a redo AF procedure (Group 2, 66 ± 8 years; 64% male; 29% paroxysmal AF). Patients undergoing first‐time pulmonary vein isolation were included in the final analysis. In these patients an endoscopically detected esophageal lesion (EDEL) was detected in 5 of 31 (16%) patients (erosion n = 2, ulcer n = 3). Mean contact force at posterior wall ablation sites was significantly lower in patients with postprocedural EDEL compared with patients without EDEL (11.9 ± 0.8 g vs. 15.6 ± 4.7 g).Conclusion: PVI using a specialized high‐power ablation catheter in conjunction with a HPSD ablation approach results in a 16% incidence of EDEL in first AF ablation candidates. Future studies evaluating high‐power short duration ablation strategies should include esophageal endoscopy to estimate the risk of clinically relevant esophageal complications.
- 13 January 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (3) , 695-703
Open AccessIncidence of ablation‐induced esophageal injury associated with high‐power short duration temperature‐controlled pulmonary vein isolation using a specialized open‐irrigated ablation catheter: A retrospective single‐center study
Introduction: To evaluate short‐term efficacy and incidence of ablation‐induced endoscopically detected esophageal injury in patients undergoing high‐power, short‐duration (HPSD) pulmonary vein isolation using a novel irrigated radiofrequency ablation catheter and ablation generator setup.Methods and Results: Atrial fibrillation (AF) patients, who underwent AF ablation using an irrigated radiofrequency ablation catheter specifically designed for a HPSD ablation approach (50 W, with a target Ablation Index of 350 at posterior wall), received postablation esophageal endoscopy after ablation. In total 45 consecutive patients (67 ± 10 years; 58% male; 42% paroxysmal AF) undergoing AF ablation using a specialized ablation catheter (QDOT) were included in the study. Thirty‐one of 45 patients (69%) underwent a first‐time pulmonary vein isolation (Group 1, 67 ± 11 years; 55% male; 48% paroxysmal AF). Fourteen patients (31%) underwent a redo AF procedure (Group 2, 66 ± 8 years; 64% male; 29% paroxysmal AF). Patients undergoing first‐time pulmonary vein isolation were included in the final analysis. In these patients an endoscopically detected esophageal lesion (EDEL) was detected in 5 of 31 (16%) patients (erosion n = 2, ulcer n = 3). Mean contact force at posterior wall ablation sites was significantly lower in patients with postprocedural EDEL compared with patients without EDEL (11.9 ± 0.8 g vs. 15.6 ± 4.7 g).Conclusion: PVI using a specialized high‐power ablation catheter in conjunction with a HPSD ablation approach results in a 16% incidence of EDEL in first AF ablation candidates. Future studies evaluating high‐power short duration ablation strategies should include esophageal endoscopy to estimate the risk of clinically relevant esophageal complications.
- 4 January 2021
- Published by Societatea Romana de Cardiologie in Romanian Journal of Cardiology
- Vol. 30 (4) , 583-588
Effective management of patients with electrical storm – networking and VT unit as essential parts for a successful outcome
Ventricular tachycardias (VT) represents worldwide one of the leading causes of sudden cardiac death. The increasing number of implanted ICDs have reduced signifi cantly the number of sudden cardiac deaths SCDs); however recurrent VTs episodes might lead to a rapid deterioration of patient’s clinical status and systolic function. An early intervention after a successful patient stabilization in a dedicated VT unit is mandatory for the mid- and long term prognosis of the patient. Nevertheless, a tight collaboration between general hospitals and highly specialized centers in treatment of patients with electrical storm is essential for an effi cient and successful outcome.
- 4 January 2021
- Published by Societatea Romana de Cardiologie in Romanian Journal of Cardiology
- Vol. 30 (4) , 583-588
Effective management of patients with electrical storm – networking and VT unit as essential parts for a successful outcome
Ventricular tachycardias (VT) represents worldwide one of the leading causes of sudden cardiac death. The increasing number of implanted ICDs have reduced signifi cantly the number of sudden cardiac deaths SCDs); however recurrent VTs episodes might lead to a rapid deterioration of patient’s clinical status and systolic function. An early intervention after a successful patient stabilization in a dedicated VT unit is mandatory for the mid- and long term prognosis of the patient. Nevertheless, a tight collaboration between general hospitals and highly specialized centers in treatment of patients with electrical storm is essential for an effi cient and successful outcome.
- 26 June 2018
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 29 (3) , 300-306
Epikardiales Mapping und Ablation bei ventrikulären Tachykardien
Ventrikuläre Tachykardien sind eine der führenden Ursachen kardialer Mortalität und bleiben die Hauptursache des plötzlichen Herztodes. Implantierbare Kardioverter-Defibrillatoren (ICD) verbessern die Überlebensprognose, aber wiederholte Therapieabgaben (v. a. ICD-Shocks) führen zu einer erhöhten Mortalität sowie zu psychologischer Beeinträchtigung. In dieser Hinsicht und basierend auf Ergebnissen multizentrischer Studien empfehlen die aktuellen europäischen Leitlinien eine frühzeitige Katheterablation bei Patienten mit rezidivierenden, anhaltenden und therapiebedürftigen VT-Episoden bei ischämischer Kardiomyopathie. Die Ablationsstrategie (isoliert endokardial oder kombiniert epi-/endokardial) hängt von dem vorliegenden strukturellen myokardialen Erkrankung ab. Fast alle Patienten mit arrhythmogener Dysplasie des rechten Ventrikels, Patienten mit Morbus Chagas sowie über 40 % der Patienten mit nichtischämischer dilatativer Kardiomyopathie (NIDCM) und einige der Patienten mit ischämischer Kardiomyopathie (v. a. bei Z. n. Hinterwandinfarkt oder großen transmuralen Vorderwandinfarkten) weisen ein epikardiales Substrat auf. Bei dieser Patientengruppe kann die isolierte endokardiale Ablation mit einem erhöhten Rezidivrisiko assoziiert und somit eine epikardiale VT-Ablation notwendig sein. Die kardiale Bildgebung (Kardio-CT/MRT) kann zuverlässig die Narbenverteilung sowie die Eigenschaften der myokardialen Vernarbung einschließlich einer möglichen epikardialen Beteiligung darstellen und somit für die Planung der Ablationsstrategie hilfreich sein. Eine epikardiale VT-Ablation sollte in spezialisierten Zentren erfolgen, da unter diesen Bedingungen die Ablation sicher und höchst effektiv durchgeführt werden kann. Ventricular tachycardia (VT) is a leading cause of cardiovascular death and remains the main cause of sudden cardiac death. Implanted cardiac defibrillators (ICD) improve survival but the recurrent ICD therapies, mostly ICD shocks, are associated with an increased mortality and deleterious psychological effects. In this regard and based on the results of multicenter studies, the current European guidelines recommend early referral for catheter ablation. The ablation strategy (isolated endocardial approach or combined epi-/endocardial) depends mostly on the underlying myocardial disease. Thus, almost all patients with right ventricular dysplasia and Chagas disease, the majority of those with dilative cardiomyopathy, and some patients with ischemic cardiomyopathy (mostly posterior wall infarction or large transmural anterior wall infarction) have an epicardial scar as the underlying substrate for recurrent VT episodes. Thus, in this group of patients, isolated endocardial VT ablation may be associated with an increased VT recurrence and therefore an epicardial approach is also needed. Cardiac imaging (cardio-CT/MRI with late enhancement[MRI LE]) can reliably identify the distribution and characteristics of the myocardial scar and may be helpful in planning the ablation strategy. When performed in highly specialized centers, epicardial catheter ablation of VT leads to a significant reduction of recurrent VT episodes compared to the endocardial VT ablation alone and with lower complication rates.
- 26 June 2018
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 29 (3) , 300-306
Epikardiales Mapping und Ablation bei ventrikulären Tachykardien
Ventrikuläre Tachykardien sind eine der führenden Ursachen kardialer Mortalität und bleiben die Hauptursache des plötzlichen Herztodes. Implantierbare Kardioverter-Defibrillatoren (ICD) verbessern die Überlebensprognose, aber wiederholte Therapieabgaben (v. a. ICD-Shocks) führen zu einer erhöhten Mortalität sowie zu psychologischer Beeinträchtigung. In dieser Hinsicht und basierend auf Ergebnissen multizentrischer Studien empfehlen die aktuellen europäischen Leitlinien eine frühzeitige Katheterablation bei Patienten mit rezidivierenden, anhaltenden und therapiebedürftigen VT-Episoden bei ischämischer Kardiomyopathie. Die Ablationsstrategie (isoliert endokardial oder kombiniert epi-/endokardial) hängt von dem vorliegenden strukturellen myokardialen Erkrankung ab. Fast alle Patienten mit arrhythmogener Dysplasie des rechten Ventrikels, Patienten mit Morbus Chagas sowie über 40 % der Patienten mit nichtischämischer dilatativer Kardiomyopathie (NIDCM) und einige der Patienten mit ischämischer Kardiomyopathie (v. a. bei Z. n. Hinterwandinfarkt oder großen transmuralen Vorderwandinfarkten) weisen ein epikardiales Substrat auf. Bei dieser Patientengruppe kann die isolierte endokardiale Ablation mit einem erhöhten Rezidivrisiko assoziiert und somit eine epikardiale VT-Ablation notwendig sein. Die kardiale Bildgebung (Kardio-CT/MRT) kann zuverlässig die Narbenverteilung sowie die Eigenschaften der myokardialen Vernarbung einschließlich einer möglichen epikardialen Beteiligung darstellen und somit für die Planung der Ablationsstrategie hilfreich sein. Eine epikardiale VT-Ablation sollte in spezialisierten Zentren erfolgen, da unter diesen Bedingungen die Ablation sicher und höchst effektiv durchgeführt werden kann. Ventricular tachycardia (VT) is a leading cause of cardiovascular death and remains the main cause of sudden cardiac death. Implanted cardiac defibrillators (ICD) improve survival but the recurrent ICD therapies, mostly ICD shocks, are associated with an increased mortality and deleterious psychological effects. In this regard and based on the results of multicenter studies, the current European guidelines recommend early referral for catheter ablation. The ablation strategy (isolated endocardial approach or combined epi-/endocardial) depends mostly on the underlying myocardial disease. Thus, almost all patients with right ventricular dysplasia and Chagas disease, the majority of those with dilative cardiomyopathy, and some patients with ischemic cardiomyopathy (mostly posterior wall infarction or large transmural anterior wall infarction) have an epicardial scar as the underlying substrate for recurrent VT episodes. Thus, in this group of patients, isolated endocardial VT ablation may be associated with an increased VT recurrence and therefore an epicardial approach is also needed. Cardiac imaging (cardio-CT/MRI with late enhancement[MRI LE]) can reliably identify the distribution and characteristics of the myocardial scar and may be helpful in planning the ablation strategy. When performed in highly specialized centers, epicardial catheter ablation of VT leads to a significant reduction of recurrent VT episodes compared to the endocardial VT ablation alone and with lower complication rates.